| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | -0.0021 | 0.9 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.0024 | 1 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.0021 | 1 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0019 | 1 |
| mRNA | BMS-345541 | CTRPv2 | pan-cancer | AAC | 0.0021 | 1 |